URBAN, MARIA LETIZIA
 Distribuzione geografica
Continente #
NA - Nord America 2.764
EU - Europa 2.297
AS - Asia 560
AF - Africa 16
SA - Sud America 3
Totale 5.640
Nazione #
US - Stati Uniti d'America 2.763
RU - Federazione Russa 1.059
IT - Italia 389
IE - Irlanda 267
SE - Svezia 199
PL - Polonia 193
SG - Singapore 182
HK - Hong Kong 121
CN - Cina 98
IN - India 55
DE - Germania 54
CH - Svizzera 42
JO - Giordania 35
IQ - Iraq 31
GB - Regno Unito 25
FI - Finlandia 16
CI - Costa d'Avorio 13
ES - Italia 13
BE - Belgio 11
AT - Austria 9
IR - Iran 9
TR - Turchia 9
UA - Ucraina 9
VN - Vietnam 9
FR - Francia 5
BR - Brasile 3
JP - Giappone 3
TW - Taiwan 3
GR - Grecia 2
KR - Corea 2
MK - Macedonia 2
NG - Nigeria 2
NL - Olanda 2
PK - Pakistan 2
CA - Canada 1
IL - Israele 1
MU - Mauritius 1
Totale 5.640
Città #
Santa Clara 845
Dublin 267
Fairfield 233
Chandler 192
Warsaw 192
Singapore 151
Ashburn 144
Woodbridge 100
Seattle 99
Houston 93
Lawrence 80
Moscow 80
Altamura 76
Cambridge 73
Wilmington 71
Ann Arbor 68
Hong Kong 68
Florence 60
Princeton 54
Mumbai 53
Boston 50
Buffalo 45
Bern 41
Baghdad 31
Beijing 28
New York 28
San Diego 25
Shanghai 23
Rome 22
Boardman 18
Medford 18
Milan 16
Abidjan 13
Kent 13
Brussels 11
Falls Church 11
Helsinki 11
Guangzhou 10
Arezzo 8
Dong Ket 8
London 8
Munich 8
Norwalk 8
Vienna 8
Yubileyny 8
Andover 7
Cagliari 7
Hillsboro 7
Los Angeles 6
Meram 6
Pamplona 6
Parma 6
Redwood City 6
Rolla 6
Bologna 5
Napoli 5
Washington 5
Barcelona 4
Campi Bisenzio 4
Castelliri 4
Genoa 4
Lappeenranta 4
Laurel 4
Venice 4
West Jordan 4
Bari 3
Frankfurt am Main 3
Menlo Park 3
Padova 3
Phoenix 3
Romola 3
Saint Petersburg 3
Sesto Fiorentino 3
Taichung 3
Acton 2
Ankara 2
Bassano del Grappa 2
Binago 2
Cinisello Balsamo 2
Fort Worth 2
Kilburn 2
Lagos 2
Montalcino 2
Paris 2
Piombino 2
Poggio Rusco 2
Prato 2
Rangsdorf 2
Romainville 2
San Venanzo 2
Seoul 2
Taiyuan 2
Tokyo 2
Treviso 2
Valencia 2
Vila Velha 2
Virle Piemonte 2
Amsterdam 1
Anguillara Sabazia 1
Barlassina 1
Totale 3.649
Nome #
Repeated low-dose courses of rituximab in SLE-associated antiphospholipid syndrome: Data from a tertiary dedicated centre 226
Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet’s syndrome 142
A large-scale genetic analysis reveals an autoimmune origin of idiopathic retroperitoneal fibrosis 125
Intravenous immunoglobulin for the secondary prevention of stillbirth in obstetric antiphospholipid syndrome: A case series and systematic review of literature 123
Association of serum C3 concentration and histologic signs of thrombotic microangiopathy with outcomes among patients with ANCA-associated renal vasculitis 111
Brief Report: Rituximab for the treatment of adult-onset IgA vasculitis (Henoch-Schönlein purpura) 111
Cutaneous sarcoidosis during rituximab treatment for microscopic polyangiitis: An uncommon adverse effect? 109
Secukinumab reduces plasma oxidative stress in psoriasis: A case-based experience 109
Cardiac involvement in eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome): Prospective evaluation at a tertiary referral centre 107
Significance of PR3-ANCA Positivity in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss) 107
Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behçet's phenotype: A multicentre study 106
Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting 104
OP0148 MEPOLIZUMAB FOR EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A RETROSPECTIVE REAL-WORLD EUROPEAN STUDY ON 142 PATIENTS 104
ModulAtion of gut Microbiota through nutritional interventions in Behçet's syndrome pAtients: the MAMBA Study 103
A unique circulating miRNA profile highlights thrombo-inflammation in Behçet's syndrome 95
Clinical and Prognostic Significance of Serum IgG4 in Chronic Periaortitis. An Analysis of 113 Patients 94
Fcγ-receptor 3B (FCGR3B) copy number variations in patients with eosinophilic granulomatosis with polyangiitis 94
Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis 94
Asbestos and Smoking as Risk Factors for Idiopathic Retroperitoneal Fibrosis 90
Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome) 89
Comparison of treatments for the prevention of fetal growth restriction in obstetric antiphospholipid syndrome: a systematic review and network meta-analysis 89
Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study 88
Obstetric antiphospholipid syndrome is not associated with an increased risk of subclinical atherosclerosis 88
Rituximab for chronic periaortitis without evidence of IgG4-related disease: A long-term follow-up study of 20 patients 88
Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes 84
Adalimumab effectiveness in Behçet’s disease: short and long-term data from a multicenter retrospective observational study 84
298. RITUXIMAB FOR DIFFICULT-TO-TREAT CHRONIC PARIAORTITIS: A CASE-SERIES OF 20 PATIENTS 83
Fibrocytes in Chronic Periaortitis: A Novel Mechanism Linking Inflammation and Fibrosis 83
Neutrophil-mediated mechanisms of damage and in vitro protective effect of colchicine in non-vascular Behçet's syndrome 82
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort 82
Association of a polymorphism of the Fcγ-receptor 2A (FCGR2A) gene with chronic periaortitis 81
135. ATHERO-THROMBOTIC AND VENOUS EVENTS (AVTE) IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A MULTICENTRE STUDY OF 573 ITALIAN PATIENTS 81
POS1212 SARS-CoV-2 INFECTION AMONG PATIENTS WITH BEHÇET’S SYNDROME 80
Unveiling the efficacy, safety, and tolerability of anti-interleukin-1 treatment in monogenic and multifactorial autoinflammatory diseases 80
Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis 79
Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study 78
New perspectives in eosinophilic granulomatosis with polyangiitis (EGPA): report of the first meeting of the European EGPA Study Group 77
Evidence of subclinical atherosclerosis in Eosinophilic Granulomatosis with Polyangiitis (EGPA) 76
Prevalence and clinical course of SARS-CoV-2 infection in patients with Behçet's syndrome 75
Chronic periaortitis with thoracic aorta and epiaortic artery involvement: a systemic large vessel vasculitis? 71
Rituximab therapy for chronic periaortitis 70
Idiopathic Mediastinal Fibrosis: a Systemic Immune-Mediated Disorder. A Case Series and a Review of the Literature 70
SARS-CoV-2 infection among patients with systemic autoimmune diseases 69
Slowly progressive ANCA-associated renal vasculitis. Clinico-pathological characterisation and outcome 67
Prevalence and clinical associations of ultrasound-confirmed enthesitis in systemic lupus erythematosus 66
Anifrolumab In Refractory Systemic Lupus Erythematosus: A Real-Life, Multicenter Study 65
Pathophysiology of IgG4-related disease: A T follicular helper cells disease? 62
Treatment of idiopathic retroperitoneal fibrosis 61
Occupational Exposures and Smoking in Eosinophilic Granulomatosis With Polyangiitis: A Case–Control Study 60
Pharmacological interventions for the prevention of fetal growth restriction: a systematic review and network meta-analysis 59
Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis 59
Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients 58
Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases 56
FCGR3B polymorphism predicts relapse risk in eosinophilic granulomatosis with polyangiitis 55
Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study-Joint and Skin (BeRLiSS-JS) 54
Idiopathic and secondary forms of retroperitoneal fibrosis: A diagnostic approach 54
Persistent Isolated C3 Hypocomplementemia as a Strong Predictor of End-Stage Kidney Disease in Lupus Nephritis 52
Management of pregnancy in autoimmune rheumatic diseases: maternal disease course, gestational and neonatal outcomes and use of medications in the prospectiveItalian P-RHEUM.it study 51
Clinical Delphi on aPL Negativization: Report from the APS Study Group of the Italian Society for Rheumatology (SIR-APS) 50
Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis with Polyangiitis: data from a European Collaborative Study 50
Dupilumab for relapsing or refractory sinonasal and/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a European retrospective study 48
Complement blockade in ANCA-associated vasculitis: an index case, current concepts and future perspectives 47
Validation of the Italian version of the ANCA-associated vasculitis patient-reported outcome (AAV-PRO) questionnaire 46
SIRT1 and thrombosis 45
The impact of environmental factors on aetiopathogenesis and clinical manifestations of Behçet's syndrome 44
Validity of Machine Learning in Predicting Giant Cell Arteritis Flare After Glucocorticoids Tapering 44
Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study 43
The management of transitional care of patients affected by phenylketonuria in Italy: Review and expert opinion 42
Optical coherence tomography angiography findings in patients affected by giant cell arteritis, with and without ocular involvement: a pilot study 39
Association between idiopathic retroperitoneal fibrosis and autoimmune thyroiditis: A case–control study 37
Systemic Fibroinflammatory Disorders - Diffuse (Thoraco-Abdominal) Periaortitis 35
Disease activity at conception predicts lupus flare up to two years after birth: A multicentre long term follow-up study 31
Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial 30
Long-term outcome of a cohort of Italian patients affected with alpha-Mannosidosis 28
Editorial: New insights into pathophysiology and management of pregnancy in systemic autoimmune diseases: Toward new therapeutic approaches 27
Fc gamma-receptor 3B (FCGR3B) copy number variations in patients with eosinophilic granulomatosis with polyangiitis 26
Fibrosis - A Common Pathway to Organ Injury and Failure 24
Evaluation of lupus anticoagulant, damage, and remission as predictors of pregnancy complications in systemic lupus erythematosus: the French GR2 study 20
Towards needed improvements in inherited metabolic medicine in adulthood: The SIMMESN adult metabolic working group and MetabERN Joint Position Statement 19
Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Behçet's syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial 8
Glucocorticoids versus glucocorticoids plus cyclophosphamide in eosinophilic granulomatosis with polyangiitis with poor-prognosis factors 5
Totale 5.748
Categoria #
all - tutte 22.380
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.380


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020257 0 0 0 0 19 22 30 29 29 23 23 82
2020/2021529 14 73 17 39 55 51 40 54 52 57 37 40
2021/2022513 25 9 85 19 15 56 14 42 29 20 87 112
2022/20231.179 90 255 72 53 50 203 170 68 106 12 41 59
2023/2024619 13 39 74 40 48 78 35 113 20 80 38 41
2024/20252.496 147 424 240 662 1.023 0 0 0 0 0 0 0
Totale 5.748